FDA Clearance Tracker · K193514
AUTION MAX AX-4060 Urinalysis System
Last checked: Nov 20, 2026Latest source record: Apr 13, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Apr 13, 2023
Substantially Equivalent
Time to decision
1,211 days
Received Dec 19, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K193514
- Device name
- AUTION MAX AX-4060 Urinalysis System
- Applicant
- Arkray, Inc.
- Applicant location
- Kamigyo-Ku, JP
- Received
- Dec 19, 2019
- Decided
- Apr 13, 2023
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.1340
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code JIL. The earliest in FDA's data is K770271, decided Mar 16, 1977.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K193514
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Arkray, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K232416 · Decided May 3, 2024 · 266 days after receipt
Device type: Counter, Urine Particle (LKM) · Laboratory Medicine & Pathology
K221175 · Decided Oct 17, 2022 · 175 days after receipt
Device type: Multiple Use Blood Lancet For Single Patient Use Only (QRL) · General & Plastic Surgery
K200788 · Decided May 23, 2022 · 788 days after receipt
Device type: Prescription Use Blood Glucose Meter For Near-Patient Testing (PZI) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.